Article

Modulation of Early Mitotic Inhibitor 1 (EMI1) Depletion on the Sensitivity of PARP Inhibitors in BRCA1 Mutated Triple-Negative Breast Cancer Cells

2020-06-09

Abstract excerpt

Triple negative breast cancer (TNBC) represents approximately 10–15% of all breast cancers and has a poor outcome as it lacks a receptor target for therapy, and TNBC is frequently associated with a germline mutation of BRCA1 . Poly (ADP-ribose) polymerase inhibitor (PARPi) drugs have demonstrated some effectiveness in treating BRCA1 or BRCA2 mutated breast and ovarian cancers but resistance to PARPi is common....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8252153d-411b-5b12-9bfe-5d2d1db9625d
DOI: 10.1101/2020.06.09.142026

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Modulation of Early Mitotic Inhibitor 1 (EMI1) Depletion on the Sensitivity of PARP Inhibitors in BRCA1 Mutated Triple-Negative Breast Cancer CellsDOI 10.1101/2020.06.09.142026Read

Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cellsSemantic proximity Read

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity Read

The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibitionSemantic proximity Read

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast CancerSemantic proximity Read

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cellsSemantic proximity Read

Targeting FEN1 to enhance efficacy of PARP inhibition in triple-negative breast cancerSemantic proximity Read

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatmentSemantic proximity Read

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cellsSemantic proximity Read

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor ResistanceSemantic proximity Read

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast CancerSemantic proximity Read

BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expressionSemantic proximity Read

Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancerSemantic proximity Read